Baseline variables used in the matching across all trials and baseline variables from RA-BEGIN after matching
| Baseline variables from different studies before matching | Baseline variables from RA-BEGIN after matching* | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Sample size | Age, mean (years) | Gender (%) | DAS28-ESR | Pain VAS | HAQ-DI | MTX and baricitinib effective sample size, pain/HAQ-DI | Age, mean (years) | Gender (%) | DAS28-ESR | Pain VAS | HAQ-DI |
| RA-BEGIN9 | ||||||||||||
| MTX | 210 | 51 | 70% | 6.6 | 65 | 1.7 | ||||||
| Baricitinib 4 mg | 159 | 51 | 76% | 6.6 | 64 | 1.6 | ||||||
| AMBITION/ FUNCTION 8 10 | ||||||||||||
| MTX | 571 | 50 | 80% | 6.7 | 61 | 1.49 | 179.4/160.9 | 50 | 80% | 6.7 | 61 | 1.49 |
| Tocilizumab 8 mg/kg | 578 | 50 | 79% | 6.8 | 61 | 1.59 | 142.7/147.6 | 50 | 79% | 6.8 | 61 | 1.59 |
| PREMIER 6 7 | ||||||||||||
| MTX | 257 | 52 | 74% | 6.3 | 60 | 1.5 | 181.4/180.1 | 52 | 74% | 6.3 | 60 | 1.5 |
| Adalimumab 40 mg | 274 | 52 | 77% | 6.4 | 65 | 1.6 | 151.5/153.4 | 52 | 77% | 6.4 | 65 | 1.6 |
| ORAL-START11 | ||||||||||||
| MTX | 186 | 49 | 78% | 6.6 | 59 | 1.5 | 177.8/172.8 | 49 | 78% | 6.6 | 59 | 1.5 |
| Tofacitinib 5 mg | 373 | 50 | 77% | 6.6 | 59 | 1.5 |
146.5/ 148.9 | 50 | 77% | 6.6 | 59 | 1.5 |
*Effective sample size and values for baricitinib or MTX from RA-BEGIN decreased after matching with different studies.
DAS28, Disease Activity Score for 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; VAS, visual analogue scale.